Exploratory biomarker analyses of OS in JAVELIN Bladder 100 suggested that although established biomarkers such as PD-L1 and tumor mutational burden (TMB) showed some predictive value, each biomarker alone missed important subgroups of patients who could potentially benefit from therapy [7]. Here, CD274 is linked to neoplasm.